What is HC Wainwright's Estimate for KROS FY2024 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Keros Therapeutics in a research note issued on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($5.36) per share for the year, down from their previous forecast of ($4.64). HC Wainwright currently has a "Buy" rating and a $100.00 price target on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($5.14) per share. HC Wainwright also issued estimates for Keros Therapeutics' Q4 2024 earnings at ($1.48) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.57) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.59) EPS, FY2025 earnings at ($6.21) EPS, FY2026 earnings at ($7.15) EPS, FY2027 earnings at ($8.41) EPS and FY2028 earnings at ($5.79) EPS.

A number of other research analysts have also issued reports on KROS. Scotiabank initiated coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 price target on the stock. Cantor Fitzgerald initiated coverage on Keros Therapeutics in a research report on Thursday, October 24th. They issued an "overweight" rating on the stock. Guggenheim started coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a "buy" rating and a $96.00 price target for the company. Wedbush reissued an "outperform" rating and issued a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday. Finally, Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating for the company. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $88.89.

Keros Therapeutics Stock Up 0.4 %

Shares of KROS traded up $0.24 during mid-day trading on Monday, hitting $68.15. 422,580 shares of the company traded hands, compared to its average volume of 370,804. The company has a market capitalization of $2.56 billion, a PE ratio of -13.08 and a beta of 1.23. The business has a 50 day moving average of $58.19 and a 200 day moving average of $52.13. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter last year, the business posted ($1.33) EPS. Keros Therapeutics's revenue was up 4750.0% compared to the same quarter last year.

Institutional Trading of Keros Therapeutics

Several institutional investors have recently bought and sold shares of KROS. KBC Group NV lifted its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock valued at $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics during the 2nd quarter worth about $128,000. Finally, Ameritas Investment Partners Inc. boosted its holdings in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company's stock worth $169,000 after buying an additional 324 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Carl L. Gordon sold 250,000 shares of the firm's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.90% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.